New glucose monitor put to the test for people with type 1 diabetes
NCT ID NCT07092761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new real-time continuous glucose monitoring (CGM) system to see how accurate and safe it is for adults with type 1 diabetes. About 82 participants will wear the device, and its readings will be compared to standard lab measurements. The goal is to improve diabetes management by providing reliable glucose data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 82 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Diagonsed with T1DM or T2DM * Venous blood sampling access can be established in the forearm * Capable of independently reading instructions and complying with the clinical trial requirements * Willing to sign the Informed Consent Form (ICF) Exclusion Criteria: * Severe hypoglycemia within the past 6 month * Heart failure or hemiplegic sequelae due to prior cerebrovascular disease * Severe skin conditions at the sensor wear site * Extensive systemic skin disorders * Coagulation disorders confirmed by the investigator * Anemia or abnormal hematocrit * Blood donation within the past 6 months * Pregnancy (defined as positive urine test in women ≤55 years), lactation, or plans for pregnancy within ≤30 days * Current or recent (≤1 month) participation in other clinical trials * Planned MRI/CT scans during sensor wear * Allergy to medical adhesives or alcohol * Conditions impairing comprehension of informed consent or study procedures * Other exclusionary conditions per investigator's discretion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 471003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new sensor track blood sugar with pinpoint accuracy?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- Carb showdown: which diet best controls type 1 diabetes?
- Morning workout may burn more fat and stabilize blood sugar in type 1 diabetes
- Could a simple sugar help people with type 1 diabetes exercise safely?
- New study asks: is this glucose monitor a Game-Changer for diabetes?